Takeda Pharmaceutical Company Limited 보도자료 - 뉴스와이어

기업 뉴스룸

Takeda Pharmaceutical Company Limited

제약

도쿄증권거래소 (4502)

2-17-1 Muraoka-Higashi, Fujisawa, Kanagawa 251-8555 Japan

Takeda Pharmaceutical Company Limited 보도자료

697개

RSS 이메일

9월 8일 17:39

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54319980&newsitemid=20250908503054&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK%29&index=1&md5=33a6d0633

건강 제약 개발

9월 7일 16:11

U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease

Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for VONVENDI® [von Willebrand factor (Recombinant)], expanding the indication to include ro

건강 제약 개발

7월 30일 16:11

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54297300&newsitemid=20250727920112&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&index=1&md5=17dfbb1f

건강 제약 실적

7월 23일 14:30

Takeda Receives FDA 510(k) Clearance for HyHub™ and HyHub™ Duo Devices to Simplify HYQVIA® Administration

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHub™ and HyHub™ Duo, devices for patients 17 years of age and older that allow

건강 제약

7월 23일 14:30

다케다, HyHub™ 및 HyHub™ Duo 장치에 대한 FDA 510 승인 획득해 하이큐비아® 투여 간소화

다케다(TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/))가 오늘 미국 식품의약국(Food and Drug Administration, FDA)이 17세 이상 환자용 장치인 HyHub™ 및 HyHub™ Duo에 대해 510(k) 승인을 부여했다고 발표했으며 이 장치는 가정 환경이나 임상 환경에서 바늘을 사용하지 않고 하이큐비아®(HYQVIA®)[재

건강 제약

7월 14일 16:29

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54289672&newsitemid=20250714054710&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=ea59570b113c

제약 개발

7월 1일 14:10

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a

건강 제약

6월 25일 16:20

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda’s Board of Directors has 11 members serving as e

제약 인사

6월 4일 11:40

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com%2F&esheet=54264219&newsitemid=20250603992751&lan=en-US&anchor=Takeda&index=1&md5=06ff112e45cab46a48bacf2cabee3e82) (TSE:4502/NYSE:TAK (https://cts.businesswire.co

제약

6월 2일 11:25

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.protagonist-inc.com%2F&esheet=54262872&newsitemid=20250531031305&lan=en-US&anchor=NASDAQ%3APTGX&index=1&md5=0fcba811b25

제약 개발

5월 28일 08:44

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54259352&newsitemid=20250527716937&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=9ae081bcd0be6803022dd

건강 제약 IT 과학 공모/모집

5월 18일 12:55

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

Takeda (TSE: 4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the New England Journal of Medicine (https://www.nejm.org/doi/full/10.1056/NEJMoa2405847) published data from the Phase 2b trial of oveporexton (TAK-861) in

제약 개발

5월 18일 12:55

뉴잉글랜드 의학저널, 1형 기면증 환자 대상 경구용 오렉신 수용체 2 작용제 오베포렉스턴(TAK-861) 2b상 임상시험 데이터 발표

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK (https://www.takeda.com/investors/overview/))는 오늘, 뉴잉글랜드 의학저널(New England Journal of Medicine) (https://www.nejm.org/doi/full/10.1056/NEJMoa2405847)이 1형 기면증(NT1) 환자 대상 오베포렉스턴(TAK-861)의 임상 2b상

제약 개발

5월 8일 17:06

Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54244498&newsitemid=20250427084429&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&index=1&md5=22b24009

건강 제약 실적

3월 4일 10:49

Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX (https://www.protagonist-inc.com/)) and Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced positive topline results for the Phase 3 VERIFY study, in whic

제약 개발

1월 31일 13:12

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.takeda.com&esheet=54196039&newsitemid=20250129509380&lan=en-US&anchor=Takeda&index=1&md5=98fdda2da61995100aa6dbd136297ebe) (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com

건강 바이오테크 제약 인사

1월 30일 15:50

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54191699&newsitemid=20250127274764&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&index=1&md5=5a65e385

건강 제약 실적

1월 2일 09:03

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54169696&newsitemid=20241219442534&lan=en-US&anchor=%28TSE%3A4502%2FNYSE%3ATAK%29&index=1&md5=3271d4096d8be0a4fd4a3f77d4

건강 제약

2024년 12월 13일 09:01

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54165415&newsitemid=20241211148492&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=28ea6914394d96e73809b13079c73620

건강 바이오테크 제약

2024년 12월 4일 10:45

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54160718&newsitemid=20241202182459&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=d62608a5c2c22cd62b7183bac55d22be

건강 제약 수주

2024년 11월 3일 10:30

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54142153&newsitemid=20241030235134&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&index=1&md5=85e5e59e

건강 제약 실적

2024년 11월 3일 10:30

다케다, FY2024 상반기 실적 호조 발표 및 연간 전망 상향 조정

다케다(도쿄증권거래소: 4502/뉴욕증권거래소: TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54142153&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&ind

건강 제약 실적

2024년 9월 25일 09:03

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124287&newsitemid=20240918509211&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=16edb4a5049346a2a301aaa831f191ee

건강 제약

2024년 9월 20일 09:49

Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54124174&newsitemid=20240919392083&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=6f261eac7e8b9ec91bf3f22e89891f5b

제약 개발

2024년 9월 20일 09:45

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and midd

건강 제약 경제 사업계획

2024년 9월 20일 09:45

다케다, 5개의 신규 글로벌 기업 사회적 책임 파트너십에 3200만달러 이상을 제공해 93개국에서 보건 영향력 확대

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 오늘 5개 신규 글로벌 기업 사회적 책임(Corporate Social Responsibility, CSR) 파트너에게 46억엔(약 3200만달러)을 투입했다. 이는 전 세계 저소득 및 중소득 국가(low and middle-income countries)의 의료 시스템 회복력 향상을 위한 회사의 지속적인 노력의 일환이다. 이러한 노력은

건강 제약 경제 사업계획

2024년 8월 8일 15:25

Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54104396&newsitemid=20240806343138&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=9aee08ea2369fdc74b51a

건강 제약

2024년 8월 1일 14:00

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline

Takeda (TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54099945&newsitemid=20240725145481&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&index=1&md5=9d0258d1

건강 제약 실적

2024년 8월 1일 14:00

다케다, 2024 회계연도 1분기 실적 발표… 성장 및 출시 제품에 의한 강력한 실적, 유망한 후기 단계 파이프라인의 발전

다케다(Takeda)(TOKYO:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Fstock-information%2F&esheet=54099945&lan=en-US&anchor=TOKYO%3A4502%2FNYSE%3ATAK&in

건강 제약 실적

2024년 6월 27일 14:20

Takeda Announces New Assignments of Directors

Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Ta

건강 제약 인사

2024년 6월 27일 14:20

다케다, 새로운 이사 임명 발표

다케다(Takeda)(TOKYO:4502/NYSE:TAK)가 오사카에서 개최된 제148차 정기 주주총회에 이어 이사회 회의와 감사 및 감독 위원회 회의에서 결정된 새로운 이사 선임을 발표했다. 다케다 이사회는 총 14명 중 11명이 사외이사로 재직하고 있어 투명성과 객관성을 확보하는 데 도움을 주고 있다. 사외이사는 계속해서 이사회 의장을 맡게 된다. 감사감독위원회, 추천위원회 및 보상위원회는 위원장들을 포함

건강 제약 인사

2024년 6월 25일 09:26

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54085563&newsitemid=20240624910432&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=c7e63d14e39fb7f693ab7

건강 제약

2024년 6월 23일 13:54

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) i

건강 제약 개발

2024년 6월 23일 12:47

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cance

건강 제약 개발

2024년 6월 20일 14:15

Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54067141&newsitemid=20240618911375&lan=en-US&anchor=%28TSE%3A4502%2FNYSE%3ATAK%29&index=1&md5=da23361615651a23e03e9b649c

제약 개발

2024년 6월 20일 14:15

다케다, PNS 연례회의서 만성 염증성 탈수초성 다발성 신경병증 환자 대상 ‘하이큐비아®’의 제3상 ADVANCE-CIDP 3 임상시험 장기 데이터 발표

다케다(Takeda)(TSE:4502/NYSE:TAK) (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54067141&lan=en-US&anchor=%28TSE%3A4502%2FNYSE%3ATAK%29&index=1&md5=da2

제약 개발

2024년 6월 18일 09:05

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54062720&newsitemid=20240617592767&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0d95a3fa2ef8dfe45a4f5

제약 개발

2024년 6월 16일 10:00

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54061414&newsitemid=20240614852542&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=d8d2476629cd9851b3a47b5c74ff5da5

건강 제약 수주

2024년 6월 4일 08:57

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Takeda (TSE: 4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024400&newsitemid=20240531655762&lan=en-US&anchor=TSE%3A+4502%2FNYSE%3ATAK&index=1&md5=470102c888bcbec2034

제약 조사연구

2024년 6월 2일 14:57

Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54024382&newsitemid=20240601381068&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&

제약 개발

2024년 6월 2일 13:33

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024414&newsitemid=20240531914145&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=6ddde6fba10f2313c5de7

건강 제약 조사연구

2024년 5월 15일 10:30

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

Takeda (TSE: 4502/NYSE:TAK) (https://www.takeda.com/investors/overview/) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) (https:

건강 의학 조사연구

2024년 5월 14일 09:55

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53983823&newsitemid=20240510475155&lan=en-US&anchor=Takeda&index=1&md5=4a403ee030780c54b5ebde46e786f5e8) (TSE:4502/NYSE:TAK (https://cts.businesswire.c

건강 바이오테크 제약 수주

2024년 5월 13일 10:20

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Management Guidance for Revenue and Core EPS performance

건강 제약 실적

2024년 5월 13일 10:20

다케다, FY2023 연간 실적 및 FY2024 전망 발표… 후기 단계 파이프라인 개발 및 핵심영업이익 마진 확대 위한 노력 확인

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 FY2023(2024년 3월 31일 마감) 재무 실적을 오늘 발표하며, 독점권 상실의 영향이 컸던 해에 핵심영업이익에 대한 경영 지침을 달성하고 CER에서 매출 및 핵심 EPS 실적에 대한 경영 지침을 초과했다고 밝혔다. 다케다는 성장 및 출시 제품 포트폴리오의 지속적 발전과 후기 단계 파이프라인을 통한 6가지 유망 프로그램의 진전을 통

건강 제약 실적

2024년 4월 28일 13:10

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibit

건강 제약

2024년 4월 9일 13:19

Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53923546&newsitemid=20240408059362&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=0f89a80c11bd73d71d8d1d38ee5b12a7

건강 제약 사회공헌

2024년 3월 28일 10:30

Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting

Takeda (TOKYO:4502/NYSE:TAK) today announced that its Board of Directors decided on March 26, 2024 (CET) to propose candidates for Board of Directors at the 148th Ordinary General Meeting of Shareholders to be held on June 26, 2024. Mr. Milano Fur

건강 제약 인사

2024년 3월 28일 10:30

다케다, 다가오는 주주총회에서 이사회 후보 발표

다케다(Takeda)(TOKYO:4502/NYSE:TAK)가 오늘 2024년 6월 26일에 개최되는 제148차 정기 주주총회에서 이사회가 이사회 후보를 2024년 3월 26일(중부 유럽 시간)에 제안하기로 결정했다고 발표했다. 현재 일본 제약 사업부(Japan Pharma Business Unit, JPBU)의 사장인 밀란 후루타(Milano Furuta)가 2024년 4월 1일부터 콘스탄틴 사루코스(Cons

건강 제약 인사

2024년 3월 22일 11:00

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53912461&newsitemid=20240319911372&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=fb19a9c88868fc64b9b37787ee5b836d

건강 제약

2024년 3월 22일 11:00

다케다, 새로 진단된 Ph+ ALL 성인 환자에 대한 ICLUSIG®의 신약보충허가신청의 미국 FDA 승인 발표

다케다(Takeda)(도쿄증권거래소:4502/뉴욕증권거래소:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53912461&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=fb1

건강 제약

2024년 3월 14일 10:04

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53909424&newsitemid=20240313160788&lan=en-US&anchor=Takeda&index=1&md5=6f3040795d635d91a3047b63610ac398) (TSE:4502/NYSE:TAK (https://cts.businesswire.c

제약 개발

2024년 2월 29일 15:25

Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53901571&newsitemid=20240226565897&lan=en-US&anchor=Takeda&index=1&md5=66a3b376ad586d49f3651a4e8ba4fded) (TSE:4502/NYSE:TAK (https://cts.businesswire.c

건강 제약 제휴

2024년 2월 29일 15:25

다케다, 바이올로지컬 E와 협력해 풍토병 지역 내 뎅기열 백신 이용 가속화

다케다(Takeda) (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53901571&newsitemid=20240226565897&lan=en-US&anchor=Takeda&index=1&md5=66a3b376ad586d49f3651a4e8ba

건강 제약 제휴

2024년 2월 11일 11:15

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53894240&newsitemid=20240208344780&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=4bd359732435922d86c0acfe2317f5eb

제약 개발

2024년 2월 2일 16:10

Takeda Announces Chief Financial Officer Succession

Takeda (TOKYO:4502/NYSE:TAK) today announced that Costa Saroukos, chief financial officer, has decided to leave Takeda to return to his home-country of Australia to be closer to family. Mr. Saroukos will step down as CFO, effective April 1, 2024 and

건강 제약 인사

2024년 2월 2일 16:10

다케다, 최고재무책임자 승계 발표

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)는 최고재무책임자(CFO) 코스타 사루코스(Costa Saroukos)가 다케다를 떠나 가족들과 더 가까이 지내기 위해 고국인 호주로 돌아가기로 결정했다고 오늘 발표했다. 사루코스는 2024년 4월 1일부로 최고재무책임자에서 물러나지만 2024년 6월 28일까지 이사회 이사로 회사에 남을 예정이다. 2024년 4월 1일부로 다케다의 일본제약

건강 제약 인사

2024년 2월 2일 14:40

Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the third quarter of fiscal year 2023 (period ended December 31, 2023). With year-to-date strong momentum in its Growth & Launch Products (+12.7% at CER) offsetting the significant re

건강 제약 실적

2024년 2월 2일 14:40

다케다, 2023 회계연도 3분기 실적 발표하며 성장 및 출시 제품의 강력한 모멘텀으로 연간 경영 지침을 향해 순항

다케다(TOKYO:4502/NYSE:TAK)가 2023 회계연도 3분기(2023년 12월 31일 마감 기간)의 재무실적을 발표했다. 제네릭 약품 부문 진입 기업의 상당한 매출 영향을 상쇄하는 성장 및 출시 제품(Growth & Launch Products)(CER 기준 +12.7%)의 연간 강력한 모멘텀을 통해 다케다는 연간 경영 지침을 향해 순조롭게 나아가고 있다. 다케다 최고재무책임자(CFO)인 코

건강 제약 실적

2024년 1월 31일 14:10

Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53888524&newsitemid=20240127162836&lan=en-US&anchor=%28TSE%3A4502%2FNYSE%3ATAK%29&index=1&md5=9dc9c2d32b29b77dbd101de853

제약

2024년 1월 31일 14:10

다케다의 하이큐비아®, 만성 염증성 탈수초성 다발성 신경병증(CIDP) 환자의 유지 요법으로 유럽연합 집행위원회가 승인

다케다(TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53888524&lan=en-US&anchor=%28TSE%3A4502%2FNYSE%3ATAK%29&index=1&md5=9dc9c2d32b29

제약

2024년 1월 30일 14:06

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53887989&newsitemid=20240125010746&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=cf95f538467bf030653f44a88e59a7b4

제약

2024년 1월 19일 11:00

Takeda Named Global Top Employer for Seventh Consecutive Year

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53884185&newsitemid=20240118372418&lan=en-US&anchor=Takeda&index=1&md5=60021b3805d222a8a4d5481a478ebf6e) (TSE:4502/NYSE:TAK (https://cts.businesswire.c

건강 제약 경제 취업 수상/선정

2024년 1월 19일 11:00

다케다, 7년 연속 전 세계 최우수 고용기업으로 선정

다케다(Takeda) (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53884185&newsitemid=20240118372418&lan=en-US&anchor=Takeda&index=1&md5=60021b3805d222a8a4d5481a478

건강 제약 경제 취업 수상/선정

2024년 1월 17일 14:33

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53882479&newsitemid=20240115984065&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=3906f12f85e8f3e823f929649e5470ac

건강 병원/의료 제약

2023년 12월 22일 13:59

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=53874021&newsitemid=20231221976317&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=1a3d0985a9865ad699dce

건강 바이오테크

2023년 12월 17일 10:50

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53870362&newsitemid=20231213527272&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=195a4aaab78d74eafffe49a6dc3da92d

건강 제약 개발

2023년 12월 17일 10:50

다케다, 만성 염증성 탈수초성 다발신경병증(CIDP) 환자의 하이큐비아 유지요법에 대해 긍정적 CHMP 의견 수신

다케다(도쿄증권거래소:4502/뉴욕증권거래소:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=53870362&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=195a4aaab78

건강 제약 개발

2023년 12월 6일 10:45

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has s

건강 제약 수상/선정

2023년 11월 10일 17:40

Takeda Receives U.S. FDA Approval of FRUZAQLA™ for Previously Treated Metastatic Colorectal Cancer

Takeda (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has approved FRUZAQLA™ (fruquintinib), an oral targeted therapy for adults with metastatic colorectal cancer (mCR

건강 제약 개발

2023년 11월 10일 17:40

다케다, 치료 전력 있는 전이성 대장암 환자 치료제로 FRUZAQLA™에 대한 미국 식품의약국 승인 획득

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK (https://www.takeda.com/investors/overview/))는 오늘 미국 식품의약국(FDA)이 FRUZAQLA™(프루킨티닙)를 승인했다고 발표했다. 프루자클라는 플루오로피리미딘(fluoropyrimidine-), 옥살리플라틴(oxaliplatin-), 이리노테칸(irinotecan-) 기반 화학요법, 항 VEGF(ant

건강 제약 개발

2023년 11월 10일 11:15

Takeda’s ADZYNMA Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura

Takeda (https://www.takeda.com/) (TSE:4502/NYSE:TAK (https://www.takeda.com/investors/overview/)) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the prophylactic and on-demand tr

건강 제약 의학 개발

2023년 11월 8일 10:48

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

Takeda (TSE:4502/NYSE:TAK) today announced that the company will present positive results from its randomized, double-blind, placebo-controlled, Phase 2b trial evaluating TAK-279, an investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor

건강 제약 병원/의료 조사연구

2023년 10월 27일 11:40

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the first half of fiscal year 2023 (six months ended September 30, 2023), updating reported and Core forecasts and reconfirming Management Guidance for Core change at CER. Takeda c

건강 제약 실적

2023년 10월 27일 11:40

다케다, 회계연도 2023년 상반기 실적 발표… 경영 지침 준수하며 연간 전망 수정

다케다(Takeda)(도쿄증권거래소: 4502/뉴욕증권거래소: TAK)가 오늘 회계연도 2023년 상반기(2023년 9월 30일에 마감된 6개월) 재무 실적을 발표하며, 보고 및 핵심 전망치를 조정하고 CER 기준 핵심 변경 사항에 대한 경영 지침을 재확인했다. 다케다 최고경영자인 크리스토프 웨버(Christophe Weber)는 다음과 같이 언급했다. “우리는 삶을 변혁하는 치료법을 발견하고 제공한다는 비전

건강 제약 실적